

Adriana Casallas-Vanegas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9437027/publications.pdf>

Version: 2024-02-01

8
papers

42
citations

1936888

4
h-index

2053342

5
g-index

8
all docs

8
docs citations

8
times ranked

49
citing authors

#	ARTICLE	IF	CITATIONS
1	Cyclophosphamide treatment in active multiple sclerosis. <i>Neurological Sciences</i> , 2021, 42, 3775-3780.	0.9	14
2	Rituximab efficacy at different initial and maintenance doses in neuromyelitis optica spectrum disorder: Experience from a national health institute in MĂ©xico. <i>Journal of the Neurological Sciences</i> , 2020, 419, 117204.	0.3	9
3	Severe fingolimod rebound syndrome after switching to cladribine treatment. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 40, 101938.	0.9	9
4	Rituximab as an effective therapeutic option in refractory Neuro-BehĂ©set syndrome. <i>Journal of Neuroimmunology</i> , 2020, 346, 577308.	1.1	7
5	Effect of rituximab on disease activity in latin American patients with anti-aquaporin-4 (+) neuromyelitis optica spectrum disorder. <i>Clinical Neurology and Neurosurgery</i> , 2020, 196, 106007.	0.6	3
6	Anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder associated with central nervous system tuberculosis. <i>Clinical and Experimental Neuroimmunology</i> , 2020, 11, 40-44.	0.5	0
7	Palatal tremor and intact Guillain-Mollaret triangle secondary to Hashimoto's encephalopathy. <i>Clinical and Experimental Neuroimmunology</i> , 2020, 11, 192-195.	0.5	0
8	Anti-aquaporin-4 positive-to-negative seroconversion in Latin American patients with neuromyelitis optica spectrum disorder treated with rituximab. <i>Clinical and Experimental Neuroimmunology</i> , 2021, 12, 248-252.	0.5	0